Phaco linked to posterior capsule rupture

Article

Phacoemulsification is linked to a higher rate of posterior capsule rupture in vitrectomized eyes, compared to combined vitrectomy and cataract surgery.

Phacoemulsification is linked to a higher rate of posterior capsule rupture in vitrectomized eyes, compared to combined vitrectomy and cataract surgery, claimed a paper in Retina.

Dr Jong Yeon Lee et al., Department of Ophthalmology, Gachon University Gil Hospital, Incheon, Korea, retrospectively reviewed the medical records of 54 patients who underwent cataract surgery in eyes that had previously been vitrectomized and 311 patients who experienced combined vitrectomy and cataract surgery. The main primary outcome measure was intraoperative complications during phacoemulsification and the secondary measures were preoperative and intraoperative cataract gradings.

It was discovered that the most common complication during phacoemulsification was posterior capsule rupture. The rate was higher in the sequential group than in the combined group, as was preoperative lens density.

Hard nucleus cataracts in vitrectomized eyes could have caused the higher rate of posterior capsule rupture in the sequential group.

Please click here for the abstract.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.